SLAMF7

SLAMF7 분자 정보

영어 이름SLAM family member 7시판 약물 수1
임상 약물 수8표적 별명CS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,CD319 Antigen,Novel LY9 (Lymphocyte Antigen 9) Like Protein
최고 연구 개발 단계Approved
영어 이름SLAM family member 7
표적 별명CS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,CD319 Antigen,Novel LY9 (Lymphocyte Antigen 9) Like Protein
시판 약물 수1
임상 약물 수8
최고 연구 개발 단계Approved

SLAMF7 제품 목록

  • 속성

    Protein (8)

  • 제품 라이브러리

    온라인 (8)

  • Human (6)Mouse (1)Rhesus macaque (1)

  • 태그

    His Tag (5)Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)

  • 마커

    Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)PE Labeled (2)

SLAMF7분자 배경

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7분자 별명

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital)Phase 2 ClinicalUniversity Hospital WürzburgMultiple Myeloma
상세
dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)Phase 1 ClinicalWuhan Sian Biotechnology Co LtdMultiple Myeloma
상세
BCMA-CS1 cCAR T-cell therapyPhase 1 ClinicaliCell Gene Therapeutics LLCMultiple Myeloma
상세
SA102-CAR-TSA-102; SA102Phase 1 ClinicalWuhan Sian Biotechnology Co LtdMultiple Myeloma
상세
WS-CART-CS1WS-CART-CS1Phase 1 ClinicalPaula C. & Rodger O. Riney Blood Cancer Research, Washington University School Of MedicineMultiple Myeloma
상세
MB-104MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CARPhase 1 ClinicalCity Of Hope National Medical CenterGlioblastoma; Multiple Myeloma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms
상세
CS1 Targeted CAR T-cells (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
상세
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)ClinicalWuhan BioRaid Biotechnology Co LtdHematologic Neoplasms
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
ElotuzumabPDL-063; HuLuc-63; BMS-901608ApprovedAbbvie Inc, Bristol-Myers Squibb CompanyEmplicitiUnited StatesMultiple MyelomaBristol-Myers Squibb Company2015-11-30Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia, Plasma Cell; Lymphoma; Multiple Myeloma; Polycythemia Vera; Primary Myelofibrosis; Smoldering Multiple Myeloma; Thrombocythemia, Essential
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호